New combo therapy targets breast cancer brain tumors
Disease control
Not yet recruiting
This early-phase study tests a targeted drug (trastuzumab deruxtecan) combined with precise radiation (stereotactic radiosurgery) in 20 people with HER2-positive breast cancer that has spread to the brain. The goal is to find the safest drug dose and see how well the combination …
Phase: PHASE1 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated May 12, 2026 13:41 UTC